<DOC>
	<DOCNO>NCT00556127</DOCNO>
	<brief_summary>The purpose trial evaluate efficacy safety add Rituximab dose-dense High-Dose Chemotherapy ( HDC ) Autologous Stem Cell Transplantation ( ASCT ) first line treatment young patient DLBCL Intermediate-High High risk aaIPI score</brief_summary>
	<brief_title>Rituximab Addition Chemotherapy With Autologous Stem Cell Transplantation Treatment Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>previously untreated aggressive Bcell lymphoma ( Diffuse Large BCell , Primary Mediastinal , Follicular grade III b Lymphoma ) ; age 18 60 ; IIIIV Ann Arbor stage ; 02 Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ; intermediatehigh ( IH ) high ( H ) risk score accord ageadjusted International Prognostic Index ( IPI ) . Patients Primary Mediastinal Lymphoma include advanced stage III IV disease . HIV , hepatitis B C virus seropositivity ; CNS involvement diagnosis ; abnormal renal , pulmonary hepatic function ; leave ventricular ejection fraction le 45 % ; pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Large B-cell Lymphoma</keyword>
	<keyword>Rituximab</keyword>
	<keyword>ASCT</keyword>
</DOC>